Farmakoekonomika i perspektive u Bosni i Hercegovini Tarik Čatić, mr.ph. sc. ISPOR BH Predsjednik Prva konferencija farmakoekonomike i istraživanja ishoda u BiH sa međunarodnim…

1 11 November 2010 Lessons learned from published economic evaluations in public health Matthijs van den Berg Johan Polder Ardine de Wit 2 Lessons learned from published…

1. Beyond borders Biotechnology Industry Report 2014 Unlocking value 2. To our clients and friends: A year can be a long time in the biotechnology industry. At this time…

Slide 1Understanding Private Payers & Maximizing Private Payer Reimbursement Strategies: Understanding the Process Barbara Grenell, Preferred Health Strategies Harvard…

Slide 1Pricing and paying for medicines Ad Antonisse AstraZeneca BV April 2005 Slide 2 Content The Netherlands compared to other EU countries What is the issue with medicines?…

1. HOW TO BUILD A MODEL TO PREDICT REIMBURSEMENT DECISIONS BY MAJOR HTA/CER AGENCIES Kermit Daniel, PhD – Chief Analytics Officer, Context Matters, Inc. December…

1.     JP Morgan Healthcare Conference   14  January  2014   2. Forward  looking  statements   This  document  contains  certain  forward-­looking  statements…

Slide 1 Example of Health Technology Assessment (HTA) of a therapy for the reduction of alcohol consumption David Tyas Global HEOR - Lundbeck Slide 2 Contents Introduction…

Slide 1 1 Health care policy evaluation: empirical analysis of the restrictions implied by Quality Adjusted Life Years Rosalie Viney and Elizabeth Savage CHERE, University…

Slide 1 This would the icon as seen on the website Audio Starts on this slide Estimate 5 mins total of audio Slide 2 Seattle Genetics Does Not Guarantee Coverage and/or Reimbursement…